Related Experiment Video

Updated: Apr 22, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I

Bin Song1, Weiping Ji1, Shiwei Guo1

  • 1Department of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

FEBS Letters
|October 16, 2014
PubMed

Insights

Low levels of microRNA 545 (miR-545) in pancreatic ductal adenocarcinoma (PDAC) promote tumor growth and are linked to reduced patient survival. MiR-545 directly targets RIG-I, inhibiting cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer mortality.
  • Dysregulation of microRNAs (miRNAs) is implicated in cancer development.
  • The specific role of miR-545 in PDAC pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the role of miR-545 in pancreatic ductal adenocarcinoma.
  • To determine the relationship between miR-545 levels, RIG-I protein, and patient survival in PDAC.
  • To identify the molecular mechanism by which miR-545 affects PDAC progression.

Main Methods:

  • Analysis of miR-545 levels and RIG-I protein expression in PDAC tissues.
  • In vitro studies assessing the effect of miR-545 modulation on PDAC cell line growth.
  • Luciferase reporter assays to confirm the targeting of RIG-I by miR-545.

Main Results:

  • Low miR-545 levels and high RIG-I protein expression were correlated with poor survival rates in PDAC patients.
  • Upregulation of miR-545 inhibited PDAC cell growth, while downregulation promoted it.
  • miR-545 was found to directly target the 3' untranslated region (3'UTR) of RIG-I.

Conclusions:

  • Reduced miR-545 levels contribute to PDAC progression by increasing tumor cell growth.
  • The miR-545/RIG-I axis represents a potential therapeutic target for pancreatic cancer.
  • MiR-545 acts as a tumor suppressor in pancreatic ductal adenocarcinoma through direct targeting of RIG-I.
Keywords:
Cancer growthPancreatic ductal adenocarcinomaPatients survivalRIG-ImiR-545

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.1K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

13.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K